期刊文献+

温州地区维持性血液透析患者矿物质代谢紊乱情况调查 被引量:4

Survey on mineral and bone metabolic disturbance in patients with maintenance hemodialysis
下载PDF
导出
摘要 目的了解温州地区维持性血液透析患者矿物质代谢紊乱情况及相关影响因素。方法收集2013年在温州地区长期维持性血液透析患者血钙、血磷、全段甲状旁腺激素(iPTH)的资料,并根据美国肾脏病协会指南(KDOQI)及中华医学会肾脏病学分会(CSN)制订的《慢性肾脏病矿物质和骨异常诊治指导》计算患者的血钙、血磷、iPTH的达标率,并对相关影响因素进行分析。结果共收集2 227例2013年在温州地区各家透析中心维持性血液透析患者的资料。按KDOQI指南标准,患者血钙、血磷、iPTH的达标率分别为44.90%、46.30%、27.64%,3项均达标者占6.29%;按《慢性肾脏病矿物质和骨异常诊治指导》建议,患者血钙、血磷、iPTH的达标率分别为57.66%、46.30%、61.14%,3项均达标者占16.97%。此外,三级医院维持性血液透析患者的平均血磷水平为(1.67±0.51)mmol/L,血磷达标率49.10%,二级医院患者的平均血磷水平为(1.79±0.53)mmol/L,达标率为43.22%,三级医院维持性血液透析患者的血磷达标率情况优于二级医院。血白蛋白、含钙磷结合剂的使用及透析频率是影响血钙达标的独立相关因素。患者的性别、年龄、活性维生素D的使用、透析龄及透析频率是影响血磷达标的独立相关因素。患者活性维生素D的使用是影响iPTH达标的独立相关因素。结论温州地区维持性血液透析患者矿物质代谢紊乱纠正情况与有关指南的要求仍然存在较大差距;患者性别、营养状态、透析频率、含钙磷结合剂的服用、活性维生素D的使用等是影响维持性血液透析患者矿物质代谢紊乱纠正的主要相关因素。 Objective To survey the mineral and bone metabolic disturbance and related risk factors in patients with maintenance hemodialysis (MHD). Methods Clinical data of 2227 MHD patients from different dialysis centers in Wenzhou area were collected in 2013. The compliance rate of serum calcium, phosphorus, iPTH was assessed according to US National Kidney Foundation KDOQI guideline for CKD-MBD and Chinese Society of Nephrology (CSN) guidance and the related risk factors were analyzed. Results The compliance rates of serum calcium, phosphorus and iPTH were 44.90%, 46.30% and 27.64% respectively, according to KDOQI guideline; and the compliance rate of three items was 6.29%. The compliance rates of serum calcium, phosphorus and iPTH were 57.66%, 46.30% and 61.14% respectively, according to CSN guidance; and the compliance rate of three items was 16.97%. The compliance rate of serum phosphorus in patients aged over 60 y was higher than that of other age groups. The mean value of serum phosphorus in tertiary hospitals were lower than that in secondary hospitals (1.67 ±0.51mmol/L, 1.79 ± 0.53mmol/L), and the compliance rate of serum phosphorus was higher (49.10%, 43.22%). The level of serum albumin, calcium-based phosphate binders intake, frequency of dialysis were related factors influencing compliance rate of serum calcium. Sex, age, active vitamin D intake, frequency of dialysis and dialysis duration were related factors for compliance rate of serum phosphporus. Active vitamin D intake was related factor for compliance rate of serum iPTH. Conclusion The management of serum calcium, phosphorus and iPTH for MHD patients seems to be not optimistic in different dialysis centers in Wenzhou area. Sex, nutritional status, frequency of dialysis, calcium-based phosphate binders intake, active vitamin D intake are main risk factors of mineral and bone metabolism in MHD patients.
出处 《浙江医学》 CAS 2015年第4期304-307,320,共5页 Zhejiang Medical Journal
关键词 血钙 血磷 全段甲状旁腺激素 维持性血液透析 达标率 Serum calcium Serum phosphorus Intact parathyroid hormone Maintenance hemodialysis Compliance rate
  • 相关文献

参考文献12

  • 1National Kidney Foundation. K/DOQI Clinical Practice Guide- lines for Bone Metabolism and Disease in Chronic Kidney Dis- ease[J]. American Journal of Kidney Diseases,2003,42(suppl 3): 1-202.
  • 2刘志红,王莉,陈江华,等.慢性肾脏病矿物质和骨异常诊治指导[J].中华肾脏病杂志,2014,30(增刊):14-34.
  • 3Ganesh S K, Stack A G, Levin N W, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients [J]. Journal of the American Society of Nephrology,2001,12(10):2131 -2138.
  • 4Stevens L A, Djurdjev O, Cardew S, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a func- tion of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes[J].Journal of the American Society of Nephrology, 2004, 15(3): 770-779.
  • 5Kaiantar-Zadeh K, Kuwae N, Regidor D L,et al. Survival pre- dictability of time-varying indicators of bone disease in mainte- nance hemodialysis patients[J]. Kidney International, 2006, 70(4): 771-780.
  • 6徐春萍,余碧影,杨毅,张萍,陈江华.浙江省维持性透析患者钙磷甲状旁腺激素水平调查[J].中国血液净化,2012,11(8):457-459. 被引量:2
  • 7Ryan D K,Mark D D,Vasily B, et al. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis pa- tients: a case-crossover study[J]. Pharmacoepidemiology and Drug Safety,2011,20(9):914-921.
  • 8Meric F,Yap P,Bia M J. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy[J]. American Journal of Kidney Diseases, 1990,16(5):459-464,.
  • 9孙鲁英,左力,王梅.不同钙离子浓度透析液对血液透析患者钙平衡及甲状旁腺素的影响[J].中华肾脏病杂志,2004,20(3):210-213. 被引量:51
  • 10Morduchowicz G,Sulkes J,Aizic S,et al. Compliance in hemodial- ysis patients: A multivariate regression analysis[J]. Nephron, 1993,64(3):365-373.

二级参考文献12

  • 1De Vries JPPM, Kouw PM, van der Meer NJM. Non-invasive monitoring of blood volume during hemodialysis: Its relation with post-dialytic dry weight. Kidney Int, 1993, 44: 851.
  • 2Catherine C, Philippe M, Didier B. Lung, gastric, and soft tissue uptake of Tc-99m MDP and Ga-67 citrate associated with hypercalcemia. Clin Nucl Med, 2003, 28: 467-471.
  • 3Argilés A, Mourad G. How do we have to use the calcium in the dialysate to optimize the management of secondary hyperparathyroidism? Nephrol Dial Transplant, 1998, 13 Suppl 3:62-64.
  • 4Palmer, Biff F. Individualizing the dialysate in the hemodialysis patient. Semin Dial, 2001, 14: 41-49.
  • 5Hou SH, Zhao J, Ellman CF, et al. Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis,1991, 2: 217-224.
  • 6Argilés A, Kerr PG, Canaud B, et al. Hemodialysis and hemodiaffitration Ca kinetics, and the long-term effects of lowering dialysate calcium concentration. Kidney Int, 1993, 43: 630-640.
  • 7Yudd M, Liach F. Renal osteodystrophy. In: Brenner BM, ed.Dialysis and transplantation. 北京: 科学出版社, 2001.14:259-260.
  • 8Argilés A, Mion CM. Calcium balance and intact parathormone variations during haemodiafiltration. Nephrol Dial Transplant,1995, 10: 2083-2089.
  • 9Femández E, Borràs M, Pais B, et al. Low-calcium dialysate stimulates parathormone secretion and its long-term use worsens secondary hyperparathyroidism. J Am Soc Nephrol, 1995, 6:132-135.
  • 10Merwe WM, Rodger RS, Grant AG, et al. Low calcium dialysate and high oral calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant, 1990, 5: 874-877.

共引文献52

同被引文献46

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部